Introduction
Immunoglobulin E (IgE)-mediated allergies affect more than 25% of the world's population (1) , and the prevalence of allergic diseases has doubled in the last two decades. Currently, the diagnosis of type 1 allergy is based on measurement of allergen-specific IgE antibodies (sIgE) and in-vivo provocation tests (Skin Prick Tests, Oral Provocation Tests, etc). Both methods are usually performed with natural allergen extracts or with a mix of natural allergen extracts. Allergen extracts contain the allergens of interest as well as some additional undefined non-allergenic components. Whatever the method used for diagnosis (in-vitro or in-vivo tests), the use of natural extracts does not specify which allergen the patient has been sensitized to (''major'' or ''minor'' allergens). Moreover, all these tests are unable to provide answers regarding the severity of the allergic symptoms caused by these allergens. The application of genetic engineering (molecular techniques and recombinant DNA technology) has enabled the sequencing, synthesizing and cloning of different allergenic proteins resulting in the production of recombinant allergens. The validation of recombinant allergens implies that their immunological activity with the natural allergen needs to be confirmed by in-vitro and in-vivo tests on a large number of allergic patients. The recombinant allergens have to be comparable with their natural templates with respect to structural features and immunobiological properties. Advances in allergen characterization have identified what are the potential allergenic proteins among the whole proteins in allergenic sources. A large number of allergens from various sources have been characterized in detail. The major allergen of house dust mites (Der p 1) was cloned in 1988 (2) , and is the first of many allergens. To date, more than 1700 allergens have been described and more than 900 molecules have been produced using recombinant techniques (3). Recombinant allergens have provided us with new tools that can improve the diagnosis of allergy (4) . Recombinant allergens can be used for component-resolved-diagnosis (CRD) (5) of the patient's allergen sensitization profile, whereas allergen extracts only enable identification of the allergen-containing sources. CRD permits diagnosis of the genuine sensitization of patients towards a given allergenic source, or to cross-reactive molecules that suggest cross-sensitization to several allergen sources (6, 7) . The new analytical method, the ImmunoCAP ᭧ ISAC microarray (VBC Genomics, Vienna, Austria/Phadia, Uppsala, Sweden) has been introduced recently to perform CRD assays. This microarray technique allows the determination of sIgE against more than 100 recombinant or purified allergen components from many different allergen sources in a single analytical step. Like any new method used routinely in the clinical laboratory, it is necessary to evaluate this technique. The aim of our study was to establish a comparison of the Article in press -uncorrected proof (Table 1 
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Materials and methods

Patients
We selected 86 patients (26 males, 60 females; 30.68"37.15 years) with anamnesis and a clinical diagnosis of type 1 allergy. These patients were selected on the basis of their sIgE tests for recombinant allergens performed with the Phadia ImmunoCAP ᭧ 250. The sIgE were directed against 55 recombinant or natural purified proteins (Table 1) . Next, we selected two patients with a high Tot IgE (above 10,000 kU/L) to evaluate potential non-specific binding of IgE.
This study was approved by the Ethic Committee.
ImmunoCAP ᭧ ISAC determination
All the samples were screened for an allergen-specific IgE determination by using the microarray ImmunoCAP ᭧ ISAC according to the manufacturer's recommendations. We used reagents from the ''Assay Kit IgE'' using a fluorescence-conjugated anti-human IgE (mouse monoclonal antibody). Briefly, we washed the microarray chips to remove non-covalently bound allergens from the microarray surface. Then, we applied 20 mL of patient sample or control directly onto one individual reaction site, and incubated the slides for 120 min at room temperature in a humidified chamber. Then, we washed the excess sample and then added 20 mL of fluorescence labelled anti-human IgE detection antibody. After incubating for 60 min, we washed the unbound detection antibody. We used a microarray scanner (CapitalBio ᭧ LuxScanTM 10K-A) for data acquisition. The images for each spot of the scanned chips were analyzed using MIA software (Microarray Image Analyzer). The 
Results
In all, 555 sIgE for recombinant allergens were performed with the ImmunoCAP ᭧ 250. Three hundred and eighty-four results out of 555 were positive ()0.10 kUA/L) with the CAP method, and 171 were negative (-0.10 kUA/L). With ImmunoCAP ᭧ ISAC, 302 of the 384 positive results shown by ImmunoCAP ᭧ were also found positive (concordance 78.65%). The mean of the 82 discrepant results measured with the ImmunoCAP ᭧ was 0.67"2.06 kUA/L. We found that 52 of the 82 discrepant results were below 0.35 kUA/L, the previous cut-off threshold for ImmunoCAP ᭧ 250. With this cut-off, the concordance of positive results was 92.19% (Table 2) . Of the 171 results found negative with ImmunoCAP ᭧ 250, we observed that 160 were also found negative with ISAC ᭧ (concordance 93.57%). The mean of these 11 sIgE measured with the ISAC ᭧ technique was 1.57"3.56 ISU. No non-specific binding was observed up to 150,000 kU/L. The discrepancies were more frequently observed with some specific allergens ( Table 1 ). Among those allergens for which we often observed negative results with the ImmunoCAP ᭧ ISAC method but positive results with ImmunoCAP ᭧ 250, we found rAsp f 1 (9 discrepant results out of 14 measurements), rPru p 3 (5 discrepant results out of 13 measurements), nAna c 2 (4 discrepant results out of 11 measurements), and rApi g 1 (4 discrepant results out of 10 measurements).
Discussion
In this study, we compared the results of sIgE against 555 recombinant or natural purified allergens observed with the ImmunoCAP ᭧ 250 and a new microarray technique ImmunoCAP ᭧ ISAC using samples from 86 patients. The concordance for positive results was 78.65%, and the mean of 82 discrepant results measured with the ImmunoCAP For the discrepancies we found that these were more frequently observed with some specific allergens. For instance, the recombinant rPru p 3 gave a discordant result in five of 13 samples (with a mean of the sIgE measured on ImmunoCAP ᭧ 250 of 2.14 kUA/L, a high level). This is of interest because rPru p 3 is part of the lipid transfer protein, a major allergen family (9) . Indeed, the sensitization to rPru p 3 is often associated with systemic reactions in addition to oral allergy syndrome, seen primarily in southern Europe. This protein is stable to heat and digestion, causing reactions to cooked foods. The concordance of the negative results was 93.57%. All of these discrepancies, both negative and positive, could perhaps be explained by the difference in presentation of the allergens. Indeed, allergens fixed to the matrix of the CAP ᭧ or coated to the teflon of the glass slide may not always present the epitope in the same manner. It is possible that some immobilized proteins do not allow for good recognition by the IgE antibodies.
From a specificity point of view, we found excellent specificity towards Tot IgE as no non-specific binding was observed with the microarray technique on two sera with Tot IgE )10,000 kU/L.
Regarding quality controls the management of microarray techniques is quite challenging. Indeed, it is not obvious to use quality control material that would be positive for all the proteins tested. In our opinion, the most important is the lot-to-lot variation. In this study, we used serum from a patient showing sensitization to a large amount of recombinant protein as lot control. Kricka and Master (10) recently indicated that microarray techniques require standardized protocols, and particularly focused attention on the preanalytical phase. Indeed, a single error in dilution can produce erroneous results. Another significant future challenge will be devising rules for interpreting multiplex QC data, and determining the acceptability of analytical results from an array-based assay. Analysis of susceptibility to preanalytical variation will become important as multiplexing becomes more common (11) .
Conclusions
Recently, the ImmunoCAP ᭧ ISAC allergen-microarray was introduced to run CRD. Our results show that the ImmunoCAP ᭧ ISAC performs analytically well when we compared 555 sIgE results with the results provided by the ImmunoCAP ᭧ 250 method. However, it is necessary to have a better sensitivity for some allergens, notably clinically relevant allergen components, such as rPru p 3.
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